Sunday, January 1, 2012

A portable device now available to check on Asthmatics

Medicine / Pediatrics NIOX MINO®, a hand-held device for the measurement of airway inflammation and monitoring of patients with asthma, has just been 510(k) cleared by the FDA. The device will “cost efficiently improve management and care of patients with inflammatory disorders, such as asthma.” The monitor is sensitive enough to detect as low as 5 particles per billion of exhaled nitric oxide. NIOX MINO Airway Inflammation Monitor is an easy-to-use handheld device that provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide (FENO). This is a proven and sensitive indicator of the inflammation that causes the symptoms of airway inflammatory diseases including asthma. Current management of airway inflammatory diseases, including asthma, is achieved primarily by monitoring symptoms and lung function, with the treatment objective of bringing the disease under control. But the underlying cause of these respiratory symptoms and asthma attacks is airway inflammation, which until now could not be routinely measured. NIOX MINO provides physicians in the U.S., for the first time ever, a powerful, easy-to-use tool that enables them to provide people living with inflammatory airway diseases, such as asthma, personalized inflammation control. By using NIOX MINO, doctors can provide the ideal level of therapy to each patient in order to achieve and maintain control of their symptoms. NIOX MINO answers the need for a simple, accurate tool for assessing asthma control and responsiveness to treatment. NIOX MINO helps physicians achieve asthma treatment and management goals, allowing people with asthma to enjoy greater quality of life. In its effort to increase clinicians’ awareness of fractional exhaled nitric oxide (FENO) monitoring, the company has put out the following white paper. - Posted from my iPad2

Location:Georgetown TX,United States

No comments:

Post a Comment